European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis
Open Access
- 4 November 2011
- journal article
- clinical trial
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 97 (3), 360-365
- https://doi.org/10.3324/haematol.2011.047811
Abstract
The World Health Organization classification of myeloproliferative neoplasms discriminates between essential thrombocythemia and the prefibrotic phase of primary myelofibrosis. This discrimination is clinically relevant because essential thrombocythemia is associated with a favorable prognosis whereas patients with primary myelofibrosis have a higher risk of progression to myelofibrosis or blast crisis. To assess the reproducibility of the classification, six hematopathologists from five European countries re-classified 102 non-fibrotic bone marrow trephines, obtained because of sustained thrombocytosis. Consensus on histological classification defined as at least four identical diagnoses occurred for 63% of the samples. Inter-observer agreement showed low to moderate kappa values (0.28 to 0.57, average 0.41). The percentage of unclassifiable myeloproliferative neoplasms rose from 2% to 23% when minor criteria for primary myelofibrosis were taken into account. In contrast, the frequency of primary myelofibrosis dropped from 23% to 7%, indicating that the majority of patients with a histological diagnosis of primary myelofibrosis did not fulfill the complete criteria for this disease. Thus, over 50% of cases in this series either could not be reproducibly classified or fell into the category of unclassifiable myeloproliferative neoplasms. World Health Organization criteria for discrimination of essential thrombocythemia from prefibrotic primary myelofibrosis are poorly to only moderately reproducible and lead to a higher proportion of non-classifiable myeloproliferative neoplasms than histology alone.Keywords
This publication has 21 references indexed in Scilit:
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersThe New England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Use of the World Health Organization (WHO) Classification of Non-Hodgkin's Lymphoma in Mumbai, India: A Review of 200 Consecutive Cases by a Panel of Five Expert HematopathologistsLeukemia & Lymphoma, 2004
- Value of bone marrow biopsy in the diagnosis of essential thrombocythemia.2004
- Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patientsAnnals of Hematology, 2003
- A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.1997
- Classification and Staging of Ph-negative Myeloproliferative Disorders by Histopathology from Bone Marrow BiopsiesLeukemia & Lymphoma, 1996
- Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia.1991
- The Measurement of Observer Agreement for Categorical DataBiometrics, 1977
- Some speculations on the myeloproliferative syndromes.1951